Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (GB:0Q15)
LSE:0Q15
Holding GB:0Q15?
Track your performance easily
0Q15 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$98.50 - $121.60
Previous Close$114.51
Volume4.32K
Average Volume (3M)47.20K
Market Cap
$194.99B
Enterprise Value$202.41B
Total Cash (Recent Filing)$7.79B
Total Debt (Recent Filing)$14.98B
Price to Earnings (P/E)34.4
Beta0.50
Next Earnings
Jan 22, 2025EPS Estimate
$1.34Next Dividend Ex-Date
Jan 15, 2025Dividend Yield1.96%
Share Statistics
EPS (TTM)3.29
Shares Outstanding1,734,455,213
10 Day Avg. Volume70
30 Day Avg. Volume47,199
Standard Deviation0.04
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)4.73
Price to Cash Flow (P/CF)18.00
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.91
Enterprise Value/Gross Profit9.14
Enterprise Value/Ebitda19.12
Forecast
1Y Price Target
$133.61Price Target Upside16.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Abbott Laboratories News
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PerformanceABT expects solid growth with organic sales growth of 9.5-10.0% and adjusted EPS in line with forecasts, with a favorable setup into the upcoming 4Q print.
Litigation DevelopmentsRecent favorable developments in NEC litigation could improve ABT's efforts to eventually reach a global settlement and end the litigation.
Product ExpansionTriClip's US launch was the last big step in commercializing the Fab Five roster, joining Libre, MitraClip, and Alinity to form a stronger lineup of growth drivers.
Bears Say
Financial PerformanceThe company's operating margin and core EPS, excluding COVID testing, fell slightly below Street estimates, raising concerns about financial robustness.
LitigationOngoing NEC litigation presents a persistent overhang on Abbott's stock, with additional state cases potentially extending the issue.
Sales GrowthQ3 organic sales growth of 8.2% did not meet the expected 9.2%, primarily due to challenges in nutrition and diagnostics performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.48% Insiders
24.43% Mutual Funds
21.16% Other Institutional Investors
33.99% Public Companies and
Individual Investors
0Q15 FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest share price was $98.50 and its highest was $121.60 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jan 22, 2025 which is in 31 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Oct 16, 2024. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.202 by $0.008.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.589 which represents an annual dividend yield of 1.96%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.34.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,734,455,200 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.21 in its last earnings report, beating expectations of $1.202. Following the earnings report the stock price went up 1.672%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.61 (16.68% Upside)
$133.61 (16.68% Upside)
Blogger Sentiment
Bullish
GB:0Q15 Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $18.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.48%
12-Months-Change
Fundamentals
Return on Equity
14.87%
Trailing 12-Months
Asset Growth
3.14%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
0Q15 Company Deck
---
0Q15 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant growth in several key segments, and strategic partnerships and product launches augmenting future prospects. However, some segments underperformed due to specific challenges, which the company is addressing. Despite these issues, Abbott maintained its full-year guidance and showed confidence in strong upcoming quarters.Read More>---
0Q15 Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
0Q15 Stock 12 Month Forecast
Average Price Target
$133.61
▲(16.68% Upside)
Technical Analysis
Abbott Laboratories
―
Johnson & Johnson
―
Medtronic
―
Baxter International
―
Stryker
―
Best Analysts Covering 0Q15
1 Year
1 Year Success Rate
24/26 ratings generated profit
1 Year Average Return
+19.45%
reiterated a buy rating 2 months ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +19.45% per trade.
---